Otonomy, Inc. (OTIC) Given “Hold” Rating at Piper Jaffray Companies
Piper Jaffray Companies reiterated their hold rating on shares of Otonomy, Inc. (NASDAQ:OTIC) in a research report released on Friday morning. Piper Jaffray Companies currently has a $8.00 price objective on the biopharmaceutical company’s stock.
Several other research firms have also commented on OTIC. BidaskClub lowered shares of Otonomy from a buy rating to a hold rating in a research note on Friday, August 11th. J P Morgan Chase & Co upgraded shares of Otonomy from a neutral rating to an overweight rating and set a $28.00 price target for the company in a research note on Tuesday, August 15th. Cowen and Company reiterated an outperform rating and issued a $9.00 price target (down previously from $55.00) on shares of Otonomy in a research note on Thursday, August 31st. SunTrust Banks, Inc. reiterated a buy rating and issued a $15.00 price target (down previously from $45.00) on shares of Otonomy in a research note on Thursday, August 31st. Finally, Zacks Investment Research upgraded shares of Otonomy from a sell rating to a hold rating in a research note on Friday, August 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. Otonomy has a consensus rating of Hold and an average target price of $10.00.
Otonomy (OTIC) traded up $0.05 during midday trading on Friday, hitting $5.17. 3,955,900 shares of the stock traded hands, compared to its average volume of 2,163,648. Otonomy has a twelve month low of $2.80 and a twelve month high of $21.15.
Otonomy (NASDAQ:OTIC) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.15. Otonomy had a negative net margin of 7,899.03% and a negative return on equity of 60.74%. The business had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.43 million. The company’s revenue was down 12.8% on a year-over-year basis. sell-side analysts expect that Otonomy will post -3 EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in shares of Otonomy in the 2nd quarter valued at $115,000. Legal & General Group Plc grew its position in Otonomy by 13.3% in the 2nd quarter. Legal & General Group Plc now owns 6,348 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 746 shares during the last quarter. Lakeview Capital Partners LLC purchased a new position in Otonomy in the 3rd quarter valued at $120,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Otonomy in the 3rd quarter valued at $126,000. Finally, American International Group Inc. grew its position in Otonomy by 7.1% in the 1st quarter. American International Group Inc. now owns 14,800 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 981 shares during the last quarter. 89.03% of the stock is currently owned by institutional investors.
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.